488 related articles for article (PubMed ID: 15984978)
1. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
Bibiloni R; Fedorak RN; Tannock GW; Madsen KL; Gionchetti P; Campieri M; De Simone C; Sartor RB
Am J Gastroenterol; 2005 Jul; 100(7):1539-46. PubMed ID: 15984978
[TBL] [Abstract][Full Text] [Related]
2. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
3. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.
Huynh HQ; deBruyn J; Guan L; Diaz H; Li M; Girgis S; Turner J; Fedorak R; Madsen K
Inflamm Bowel Dis; 2009 May; 15(5):760-8. PubMed ID: 19067432
[TBL] [Abstract][Full Text] [Related]
4. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
Sood A; Midha V; Makharia GK; Ahuja V; Singal D; Goswami P; Tandon RK
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1202-9, 1209.e1. PubMed ID: 19631292
[TBL] [Abstract][Full Text] [Related]
5. [Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis].
Lee JH; Moon G; Kwon HJ; Jung WJ; Seo PJ; Baec TY; Lee JH; Kim HS
Korean J Gastroenterol; 2012 Aug; 60(2):94-101. PubMed ID: 22926120
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Tursi A; Brandimarte G; Papa A; Giglio A; Elisei W; Giorgetti GM; Forti G; Morini S; Hassan C; Pistoia MA; Modeo ME; Rodino' S; D'Amico T; Sebkova L; Sacca' N; Di Giulio E; Luzza F; Imeneo M; Larussa T; Di Rosa S; Annese V; Danese S; Gasbarrini A
Am J Gastroenterol; 2010 Oct; 105(10):2218-27. PubMed ID: 20517305
[TBL] [Abstract][Full Text] [Related]
7. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
Dang X; Xu M; Liu D; Zhou D; Yang W
PLoS One; 2020; 15(3):e0228846. PubMed ID: 32182248
[TBL] [Abstract][Full Text] [Related]
8. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis.
Mardini HE; Grigorian AY
Inflamm Bowel Dis; 2014 Sep; 20(9):1562-7. PubMed ID: 24918321
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy.
Tsuda Y; Yoshimatsu Y; Aoki H; Nakamura K; Irie M; Fukuda K; Hosoe N; Takada N; Shirai K; Suzuki Y
Scand J Gastroenterol; 2007 Nov; 42(11):1306-11. PubMed ID: 17852859
[TBL] [Abstract][Full Text] [Related]
10. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
Drugs; 2006; 66(10):1371-87. PubMed ID: 16903771
[TBL] [Abstract][Full Text] [Related]
11. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.
Kühbacher T; Ott SJ; Helwig U; Mimura T; Rizzello F; Kleessen B; Gionchetti P; Blaut M; Campieri M; Fölsch UR; Kamm MA; Schreiber S
Gut; 2006 Jun; 55(6):833-41. PubMed ID: 16401690
[TBL] [Abstract][Full Text] [Related]
12. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
BioDrugs; 2007; 21(1):61-3. PubMed ID: 17263590
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis.
Ng SC; Plamondon S; Kamm MA; Hart AL; Al-Hassi HO; Guenther T; Stagg AJ; Knight SC
Inflamm Bowel Dis; 2010 Aug; 16(8):1286-98. PubMed ID: 20155842
[TBL] [Abstract][Full Text] [Related]
15. Probiotics in the Management of Ulcerative Colitis.
Chibbar R; Dieleman LA
J Clin Gastroenterol; 2015; 49 Suppl 1():S50-5. PubMed ID: 26447965
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.
Yoshimatsu Y; Yamada A; Furukawa R; Sono K; Osamura A; Nakamura K; Aoki H; Tsuda Y; Hosoe N; Takada N; Suzuki Y
World J Gastroenterol; 2015 May; 21(19):5985-94. PubMed ID: 26019464
[TBL] [Abstract][Full Text] [Related]
17. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review.
Ganji-Arjenaki M; Rafieian-Kopaei M
J Cell Physiol; 2018 Mar; 233(3):2091-2103. PubMed ID: 28294322
[TBL] [Abstract][Full Text] [Related]
18. High-dose probiotics for the treatment of active pouchitis.
Gionchetti P; Rizzello F; Morselli C; Poggioli G; Tambasco R; Calabrese C; Brigidi P; Vitali B; Straforini G; Campieri M
Dis Colon Rectum; 2007 Dec; 50(12):2075-82; discussion 2082-4. PubMed ID: 17934776
[TBL] [Abstract][Full Text] [Related]
19. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study.
Karimi O; Peña AS; van Bodegraven AA
Drugs Today (Barc); 2005 Jul; 41(7):453-9. PubMed ID: 16193098
[TBL] [Abstract][Full Text] [Related]
20. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.
Venturi A; Gionchetti P; Rizzello F; Johansson R; Zucconi E; Brigidi P; Matteuzzi D; Campieri M
Aliment Pharmacol Ther; 1999 Aug; 13(8):1103-8. PubMed ID: 10468688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
